Sanofi ‘decides not to renew’ mandate of CEO Paul Hudson

Sanofi’s (SNY) Board of Directors met on February 11, 2026, and decided not to renew the Director mandate of Paul Hudson. As a result, Paul Hudson’s last day as CEO will be on February 17, 2026 at the end of business. The Board thanks him for his valuable contributions to the transformation and development of the Group over the last six years. Following the proposal of the Appointments Committee, the Board of Directors appointed Belen Garijo as CEO. She will take up her duties at the end of the Group’s Annual General Meeting on April 29, 2026. The Board will also propose to the shareholder vote the candidacy of Belen Garijo as a director of the Group. Olivier Charmeil, Executive Vice President, General Medicines, and member of the Executive Committee since 2011, will assume the role of Interim CEO during this transition. Belen Garijo, MD, joined Merck KGaA (MKGAY) in 2011 and became its CEO in 2021.